Title
Considerations of manufacturability for AAV based gene therapy products for rare diseases
Conference Dates
February 6 – 10, 2022
Abstract
Passage Bio is developing a robust and efficient manufacturing platform to streamline the development and technology transfer of preclinical and clinical candidates to external manufacturing partners. In this presentation, we highlight Passage Bio’s approach to manufacturability for AAV vectors by advancements in cell line development, optimizing process conditions, implementation of next generation analytics, and viral clearance strategy to ensure a safe and efficacious final product. It is our goal that this work will result in a state-of-the-art process for AAV production to facilitate rapid transition toward pre-commercial development and build out a robust gene therapy pipeline.
Recommended Citation
Nripen Singh, "Considerations of manufacturability for AAV based gene therapy products for rare diseases" in "Advancing Manufacture of Cell and Gene Therapies VII", Sharon Brownlow, Cell & Gene Therapy Catapult, UK; Sean Palecek, University of Wisconsin, USA; Damian Marshall, Achilles Therapeutics, UK; Fernanda Masri, Cell & Gene Therapy Catapult, UK Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/cellgenetherapies_vii/66